SCHEMBL24809278

SCHEMBL24809278

CSc1ncc2c(Br)ccc(O)c2n1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 5/20 0.38
HASPIN Q8TF76 2/20 0.38
OPRK1 P41145 1/20 0.38
NQO2 P16083 1/20 0.38
MEN1 O00255 4/20 0.37
NPC1 O15118 1/20 0.37
RAB9A P51151 1/20 0.37
PIM1 P11309 3/20 0.33
TTK P33981 3/20 0.33
PIM2 Q9P1W9 3/20 0.33
ALDH1A1 P00352 2/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
MAPK1 P28482 1/20 0.33
NTRK1 P04629 1/20 0.32
CTSB P07858 1/20 0.32
CTSH P09668 1/20 0.32
THRB P10828 2/20 0.31
RXFP1 Q9HBX9 1/20 0.31
POLB P06746 1/20 0.31
TDP1 Q9NUW8 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30862166 1.00 KMT2A (0.38) KMT2AHASPINOPRK1NQO2MEN1
SCHEMBL25903681 0.78 NQO2 (0.43) KMT2AOPRK1NQO2MEN1NPC1
SCHEMBL30527151 0.78 NQO2 (0.43) KMT2AOPRK1NQO2MEN1NPC1
SCHEMBL31082619 0.76 TP53 (0.42) KMT2AMEN1ALDH1A1THRBRXFP1
SCHEMBL25096317 0.76 TP53 (0.42) KMT2AMEN1ALDH1A1THRBRXFP1
SCHEMBL1635008 0.75 NQO2 (0.41) KMT2AOPRK1NQO2MEN1NPC1
SCHEMBL30862165 0.73 HASPIN (0.33) HASPIN
SCHEMBL24810080 0.73 HASPIN (0.33) HASPIN
SCHEMBL26341085 0.72 MEN1 (0.38) KMT2AHASPINMEN1ALDH1A1L3MBTL1
SCHEMBL13271289 0.71 METAP2 (0.50) KMT2AHASPINMEN1NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117836286-A Heterocyclic EGFR inhibitors for the treatment of cancer 缆图药品公司 2024-04-05 CN disclosed
WO-2022271613-A1 HETEROCYCLIC EGFR INHIBITORS FOR USE IN THE TREATMENT OF CANCER BLUEPRINT MEDICINES CORPORATION (US) 2022-12-29 WO disclosed